PARP1 and malignant colon neoplasm: The reports of the potent sensitizing effect of ATR inhibitors, including VE-821, on chemotherapy (Reaper et al., 2011) prompted us to assess the effect of the combination of ABT-888 and VE-821, targeting PARP and ATR, respectively, on irinotecan cytotoxicity in colon cancer cells.